InnoCare Pharma Limited
InnoCare Pharma Limited Fundamental Analysis
InnoCare Pharma Limited (INCPF) shows moderate financial fundamentals with a PE ratio of -81.85, profit margin of -16.07%, and ROE of -3.42%. The company generates $1.2B in annual revenue with strong year-over-year growth of 36.68%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 31.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze INCPF's fundamental strength across five key dimensions:
Efficiency Score
WeakINCPF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentINCPF trades at attractive valuation levels.
Growth Score
ExcellentINCPF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentINCPF maintains a strong and stable balance sheet.
Profitability Score
WeakINCPF struggles to sustain strong margins.
Key Financial Metrics
Is INCPF Expensive or Cheap?
P/E Ratio
INCPF trades at -81.85 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, INCPF's PEG of 1.67 indicates fair valuation.
Price to Book
The market values InnoCare Pharma Limited at 2.82 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -90.59 times EBITDA. This is generally considered low.
How Well Does INCPF Make Money?
Net Profit Margin
For every $100 in sales, InnoCare Pharma Limited keeps $-16.07 as profit after all expenses.
Operating Margin
Core operations generate -19.67 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-3.42 in profit for every $100 of shareholder equity.
ROA
InnoCare Pharma Limited generates $-2.41 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
InnoCare Pharma Limited generates limited operating cash flow of $-80.69M, signaling weaker underlying cash strength.
Free Cash Flow
InnoCare Pharma Limited generates weak or negative free cash flow of $-119.58M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.08 in free cash annually.
FCF Yield
INCPF converts -0.89% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-81.85
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.67
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.82
vs 25 benchmark
P/S Ratio
Price to sales ratio
11.15
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.03
vs 25 benchmark
ROA
Return on assets percentage
-0.02
vs 25 benchmark
ROCE
Return on capital employed
-0.03
vs 25 benchmark
How INCPF Stacks Against Its Sector Peers
| Metric | INCPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -81.85 | 29.45 | Better (Cheaper) |
| ROE | -3.42% | 779.00% | Weak |
| Net Margin | -16.07% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.25 | 0.26 | Neutral |
| Current Ratio | 6.54 | 4.65 | Strong Liquidity |
| ROA | -2.41% | -19344.00% (disorted) | Weak |
INCPF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews InnoCare Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
59821.56%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
84.75%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-239.29%
Industry Style: Defensive, Growth, Innovation
Declining